title: [Familial combined hyperlipidemia: consensus document].
abstract: Familial combined hyperlipidemia (FCH) is a frequent disorder associated with premature coronary artery disease. It is transmitted in an autosomal dominant manner, although there is not a unique gene involved. The diagnosis is performed using clinical criteria, and variability in lipid phenotype and family history of hyperlipidemia are necessaries. Frequently, the disorder is associated with type2 diabetes mellitus, arterial hypertension and central obesity. Patients with FCH are considered as high cardiovascular risk and the lipid target is an LDL-cholesterol <100mg/dL, and <70mg/dL if cardiovascular disease or type 2 diabetes are present. Patients with FCH require lipid lowering treatment using potent statins and sometimes, combined lipid-lowering treatment. Identification and management of other cardiovascular risk factors as type 2 diabetes and hypertension are fundamental to reduce cardiovascular disease burden. This document gives recommendations for the diagnosis and global treatment of patients with FCH directed to specialists and general practitioners.
authors.affiliation: Fundación Hipercolesterolemia Familiar, Madrid, España. Electronic address: pmata@colesterolfamiliar.org.
authors.forename: Pedro
authors.initials: P
authors.lastname: Mata
authors.affiliation: Clínica de Lípidos, Medicina Interna, IIS-Fundación Jiménez Díaz, Madrid, España.
authors.forename: Rodrigo
authors.initials: R
authors.lastname: Alonso
authors.affiliation: Atención Primaria, Unidad de Lípidos y Prevención Cardiovascular, Centro de Salud, Pinto, Madrid, España.
authors.forename: Antonio
authors.initials: A
authors.lastname: Ruíz-Garcia
authors.affiliation: Clínica de Lípidos, Medicina Interna, Hospital Abente y Lago, A Coruña, España.
authors.forename: Jose L
authors.initials: JL
authors.lastname: Díaz-Díaz
authors.affiliation: Departamento de Endocrinología y Nutrición, Hospital Universitario La Paz, Madrid, España.
authors.forename: Noemí
authors.initials: N
authors.lastname: González
authors.affiliation: Centro de Salud Cerro del Aire, Majadahonda, Universidad Autónoma, Majadahonda, Madrid, España.
authors.forename: Teresa
authors.initials: T
authors.lastname: Gijón-Conde
authors.affiliation: Departamento de Endocrinología, Hospital Central de Asturias, Oviedo, Asturias, España.
authors.forename: Ceferino
authors.initials: C
authors.lastname: Martínez-Faedo
authors.affiliation: Centro de Salud de Goya, Madrid, España.
authors.forename: Ignacio
authors.initials: I
authors.lastname: Morón
authors.affiliation: Centro de Salud San Blas, Parla, Madrid, España.
authors.forename: Ezequiel
authors.initials: E
authors.lastname: Arranz
authors.affiliation: Departamento de Endocrinología, Hospital Universitario de León, León, España.
authors.forename: Rocío
authors.initials: R
authors.lastname: Aguado
authors.affiliation: Departamento de Endocrinología, Hospital de Lugo, Lugo, España.
authors.forename: Rosa
authors.initials: R
authors.lastname: Argueso
authors.affiliation: Unidad de Imagen Cardiovascular, Servicio de Cardiología, Hospital Clínico San Carlos, Madrid, España.
authors.forename: Leopoldo
authors.initials: L
authors.lastname: Perez de Isla
mesh_terms: D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D006950:Hyperlipidemia, Familial Combined / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D006973:Hypertension / Q000453:epidemiology; D009765:Obesity / Q000453:epidemiology; D012307:Risk Factors
chemical_list: D000924:Anticholesteremic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
keywords: Cardiovascular disease; Consensus paper; Diabetes mellitus tipo 2; Documento de consenso; Enfermedad cardiovascular; Familial combined hyperlipidemia; Hiperlipidemia familiar combinada; Hipertensión; Hypertension; Lipid-lowering treatment; Tratamiento hipolipemiante; Type 2 diabetes mellitus